Small, Sleek, Ambitious: ViCentra Raises $85M To Develop Kaleido 2 Insulin Pump, Eyes US Market

 
• By Marion Webb
  
ViCentra's Kaleido has more than 3,500 users and CEO Tom Arnold expects "tens of thousands" of people with diabetes will be using the system in the next 18 months. (ViCentra /ViCentra)

More from Interviews

More from Europe